Skip to main content
Premium Trial:

Request an Annual Quote

InforMax Warns of Significant Q1 Revenue Drop

For an updated version of this story, please click here.


NEW YORK, April 5 -   InforMax on Thursday blamed a lack of bookings and delayed and deferred purchase decisions by potential customers for a weakened first-quarter that includes significantly lower revenue and a widened net loss.

The company said that revenue for the quarter ended March 31 will be $3.7 million, a 44 percent drop from the $6.6 million it reported during the same period one year ago. Total bookings fell off 45 percent to $3.9 million, it said.

Informax said it now expects a loss of $6.9 million, or $.27 to $.28 a share, excluding noncash charges related to stock-based compensation and a $775,000 charge tied to organizational restructuring.

The is a significant slide: In February, InforMax said it expected a loss of $.20 to $.22 per share before items. Analysts were expecting a loss of $.21 per share.


The firm has scheduled a conference call this morning.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.